what are the hurdles to using cell of origin in classification to treat dlbcl?
Published 8 years ago • 1.1K plays • Length 20:02Download video MP4
Download video MP3
Similar videos
-
9:30
debate: should dlbcl patients be treated differently based on cell of origin? - no
-
12:05
debate: should dlbcl patients be treated differently based on cell of origin? - yes
-
6:37
what are the subtypes of dlbcl?
-
20:48
current upfront management of dlbcl
-
7:24
lymphoma: overview of classification
-
4:58
doctor explains warning symptoms and signs of hodgkin's lymphoma cancer
-
19:02
i had symptoms for months! samantha's non-hodgkin lymphoma story | the patient story
-
5:30
why the 400m hurdles is one of the hardest olympic races
-
24:24
double-hit dlbcl
-
1:06
recognizing the heterogeneity of dlbcl
-
11:59
savannah sutherland advances to 400m hurdles finals at paris olympics (aug. 6, 2024)
-
5:02
what are common symptoms of dlbcl?
-
15:16
debate: how should patients with abc type dlbcl be treated today? - r-chop
-
16:21
should r-chop remain the standard of care for dlbcl?
-
12:21
non-hodgkin lymphoma - causes, symptoms, diagnosis, treatment, pathology
-
3:01
how the treatment of dlbcl and fl are changing in the uk
-
18:04
what is the best approach to treat double hit/double protein expression dlbcl?
-
18:54
how should we treat double hit and double expressor dlbcl?
-
4:26
non-hodgkin lymphoma: symptoms & treatment | stanford
-
1:38
using pet to predict failure to salvage therapy in patients with dlbcl
-
4:01
first- and second-line treatment in dlbcl
-
6:42
diffuse large b-cell lymphoma - diagnosis& treatment - aggressive b-cell non-hodgkin’s lymphoma